{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:13:50Z","timestamp":1791389630111,"version":"4.3.3"},"reference-count":60,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["P01 AI031596"],"award-info":[{"award-number":["P01 AI031596"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["P01 AI054955"],"award-info":[{"award-number":["P01 AI054955"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R01 AI088729"],"award-info":[{"award-number":["R01 AI088729"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R21 AI056974"],"award-info":[{"award-number":["R21 AI056974"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R34 AI081875"],"award-info":[{"award-number":["R34 AI081875"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["P01 AI031596"],"award-info":[{"award-number":["P01 AI031596"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["P01 AI054955"],"award-info":[{"award-number":["P01 AI054955"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01 AI088729"],"award-info":[{"award-number":["R01 AI088729"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["R21 AI056974"],"award-info":[{"award-number":["R21 AI056974"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["R34 AI081875"],"award-info":[{"award-number":["R34 AI081875"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["P01 AI031596"],"award-info":[{"award-number":["P01 AI031596"]}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["P01 AI054955"],"award-info":[{"award-number":["P01 AI054955"]}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["R01 AI088729"],"award-info":[{"award-number":["R01 AI088729"]}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["R21 AI056974"],"award-info":[{"award-number":["R21 AI056974"]}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["R34 AI081875"],"award-info":[{"award-number":["R34 AI081875"]}]},{"name":"American Lebanese Syrian Associated Charities (ALSAC)","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Human parainfluenza virus type 1 (hPIV-1) is a major cause of serious respiratory diseases in young children. Annually, hPIV-1 results in approximately 10,000 hospitalizations in the United States due to croup, bronchiolitis, and\/or pneumonia, and 10,000 deaths worldwide due to acute lower respiratory tract infections among children less than 5 years of age. Despite the burden of disease, no vaccine for hPIV-1 is currently approved. Sendai virus (SeV) is a murine PIV-1. It has structural similarities with hPIV-1 and is currently under clinical development as an hPIV-1 Jennerian vaccine. Attributes of SeV include the following: (a) needleless delivery, (b) rapid and durable serum antibody responses after a single intranasal administration, (c) durable IgG and IgA responses in the nasal mucosa, and (d) use as a platform for recombinant vaccines against multiple pediatric pathogens. Evaluation of the tolerability, safety, and immunogenicity of intranasal SeV in healthy adults and seropositive children 3 to 6 years of age was previously conducted and supported vaccine advancement to evaluation in younger children. Methods: Three seropositive children 1 to 2 years of age received a single intranasal dose of 5 \u00d7 105 EID50 SeV (SENDAI, Clinicaltrials.gov NCT00186927). Adverse events were collected for 28 days post-vaccine administration using diary cards and participants were followed for six months in total. Sera were collected longitudinally for clinical laboratory and virus-specific antibody tests. Nasal swabs were collected longitudinally for virus and mucosal antibody tests. Results: Intranasal SeV was well tolerated, with only mild grade 1\u20132 events that resolved spontaneously. No serious adverse events, medically attended adverse events, or adverse events causing protocol termination were reported. One participant had positive nasal swabs for inoculated SeV during the first week after vaccination. Although children had measurable PIV-1-specific serum antibodies at baseline, intranasal SeV vaccination resulted in significant serum antibody increases in all participants. Similarly, there were significant increases in PIV-1-specific nasal IgG and IgA levels in all participants. Elevated antibody levels persisted through the six months of follow-up. Conclusions: Intranasal SeV was well tolerated and uniformly immunogenic in seropositive children 1 to 2 years of age. Results encourage the further evaluation of SeV and SeV-based recombinants as potential intranasal vaccines for the prevention of infection by hPIV-1 and other serious respiratory pathogens.<\/jats:p>","DOI":"10.3390\/vaccines13040430","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:31:36Z","timestamp":1745181096000},"page":"430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1"],"prefix":"10.3390","volume":"13","author":[{"given":"Elisabeth","family":"Adderson","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim J.","family":"Allison","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Branum","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Sealy","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart G.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri L.","family":"Surman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon R.","family":"Penkert","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"},{"name":"Department of Chemistry and Biochemistry, Institute of Molecular Biology, University of Oregon, Eugene, OR 97403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-4115","authenticated-orcid":false,"given":"Randall T.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-3990","authenticated-orcid":false,"given":"Charles J.","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"},{"name":"Department of Host-Microbe Interactions, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Portner","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Slobod","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"},{"name":"Cambridge ID & Immunology Consulting LLC., Sommerville, MA 02144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia L.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Khales, P., Razizadeh, M.H., Ghorbani, S., Moattari, A., Saadati, H., and Tavakoli, A. (2025). Prevalence of respiratory viruses in children with respiratory tract infections during the COVID-19 pandemic era: A systematic review and meta-analysis. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03587-z"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcv.2011.07.017","article-title":"Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model","volume":"52","author":"Gaunt","year":"2011","journal-title":"J. Clin. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/00006454-200107000-00003","article-title":"Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States","volume":"20","author":"Counihan","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Russell, C.J., and Hurwitz, J.L. (2021). Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses. Viruses, 13.","DOI":"10.3390\/v13061023"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jpids\/piu047","article-title":"Estimates of Parainfluenza Virus-Associated Hospitalizations and Cost Among Children Aged Less Than 5 Years in the United States, 1998-2010","volume":"5","author":"Abedi","year":"2016","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1542\/peds.71.6.871","article-title":"Croup: An 11-year study in a pediatric practice","volume":"71","author":"Denny","year":"1983","journal-title":"Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(20)30393-4","article-title":"Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: A systematic review and modelling study","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1077","DOI":"10.1016\/S2214-109X(21)00218-7","article-title":"Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/ped.2024.0025","article-title":"Nirsevimab: A Review","volume":"37","author":"Balbi","year":"2024","journal-title":"Pediatr. Allergy Immunol. Pulmonol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Makan-Murphy, N., Madhi, S.A., and Dangor, Z. (2024). Safety, Efficacy, and Effectiveness of Maternal Vaccination against Respiratory Infections in Young Infants. Semin. Respir. Crit. Care Med.","DOI":"10.1055\/a-2471-6906"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Evong, Y., Luo, J., Ye, L., Fahey, J., Breeze, J., Attenborough, R., Wong, K., and Langley, J.M. (2025). Increased respiratory syncytial virus-associated hospitalizations and ambulatory visits in very preterm infants in the first year of life following discontinuation of access to palivizumab. Am. J. Perinatol.","DOI":"10.1055\/a-2512-9453"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ofae723","DOI":"10.1093\/ofid\/ofae723","article-title":"Maternal-Infant Respiratory Syncytial Virus and Influenza A Virus Antibody Transfer in Preterm and Full-term Infants","volume":"12","author":"Rumfelt","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/S0264-410X(03)00341-4","article-title":"Measles and mumps vaccination as a model to investigate the developing immune system: Passive and active immunity during the first year of life","volume":"21","author":"Gans","year":"2003","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/j.vaccine.2005.04.035","article-title":"Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys","volume":"23","author":"Bartlett","year":"2005","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/jpids\/piu104","article-title":"Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children","volume":"4","author":"Karron","year":"2015","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_22","first-page":"e68594","article-title":"Jenner\u2019s Legacy: How Edward Jenner\u2019s Smallpox Vaccine Changed Public Health","volume":"16","author":"Choudhari","year":"2024","journal-title":"Cureus"},{"key":"ref_23","first-page":"17","article-title":"Mass vaccination and surveillance\/containment in the eradication of smallpox","volume":"304","author":"Lane","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.virusres.2011.09.023","article-title":"Biological feasibility of measles eradication","volume":"162","author":"Bellini","year":"2011","journal-title":"Virus Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1002\/rmv.2409","article-title":"Global polio eradication; can we replicate the smallpox success story?","volume":"33","author":"Javed","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1099\/vir.0.036988-0","article-title":"The polio-eradication programme and issues of the end game","volume":"93","author":"Minor","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s00705-017-3311-7","article-title":"Taxonomy of the order Mononegavirales: Update 2017","volume":"162","author":"Amarasinghe","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.virol.2010.12.017","article-title":"Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut","volume":"410","author":"Rudraraju","year":"2011","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1016\/j.vaccine.2010.07.068","article-title":"Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1","volume":"28","author":"Sealy","year":"2010","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0065-3527(08)60103-7","article-title":"Sendai virus","volume":"23","author":"Ishida","year":"1978","journal-title":"Adv. Virus Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.4049\/jimmunol.171.7.3338","article-title":"Cutting edge: Effector memory CD8+ T cells in the lung airways retain the potential to mediate recall responses","volume":"171","author":"Ely","year":"2003","journal-title":"J. Immunol."},{"key":"ref_32","unstructured":"Knipe, D.M., and Howley, P.M. (2001). Parainfluenza viruses. Fields Virology, Lippincott Williams and Wilkins. [4th ed.]."},{"key":"ref_33","unstructured":"Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., and Straus, S.E. (2007). Parainfluenza Viruses. Fields Virology, Lippincott Williams and Wilkins."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1099\/0022-1317-83-6-1377","article-title":"Primary replication of a recombinant Sendai virus vector in macaques","volume":"83","author":"Kano","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2006.03.012","article-title":"Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment","volume":"121","author":"Bousse","year":"2006","journal-title":"Virus Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1128\/JVI.00853-08","article-title":"Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates","volume":"82","author":"Bartlett","year":"2008","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Roy, A., Chan Mine, E., Gaifas, L., Leyrat, C., Volchkova, V.A., Baudin, F., Martinez-Gil, L., Volchkov, V.E., Karlin, D.G., and Bourhis, J.M. (2023). Orthoparamyxovirinae C Proteins Have a Common Origin and a Common Structural Organization. Biomolecules, 13.","DOI":"10.20944\/preprints202301.0217.v1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Stevens, C.S., Carmichael, J., Watkinson, R., Kowdle, S., Reis, R.A., Hamane, K., Jang, J., Park, A., Pernet, O., and Khamaikawin, W. (2024). A temperature-sensitive and interferon-silent Sendai virus vector for CRISPR-Cas9 delivery and gene editing in primary human cells. bioRxiv.","DOI":"10.1101\/2024.05.03.592383"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.2741\/3054","article-title":"Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen","volume":"13","author":"Yonemitsu","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7883\/yoken.JJID.2002.59","article-title":"Induction of HIV-1-specific neutralizing antibodies in mice vaccinated with a recombinant Sendai virus vector","volume":"55","author":"Kano","year":"2002","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.36233\/0507-4088-172","article-title":"[Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow]","volume":"68","author":"Kudrov","year":"2023","journal-title":"Vopr. Virusol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00109-019-01844-3","article-title":"Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines","volume":"97","author":"Hu","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rvsc.2015.12.009","article-title":"Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus","volume":"104","author":"Zhang","year":"2016","journal-title":"Res. Vet. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Le, T.V., Mironova, E., Garcin, D., and Compans, R.W. (2011). Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018780"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1016\/j.vaccine.2009.08.026","article-title":"Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2","volume":"27","author":"Duan","year":"2009","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1016\/j.vaccine.2007.10.038","article-title":"Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B","volume":"25","author":"Zhan","year":"2007","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.vaccine.2011.11.046","article-title":"Sendai virus-based RSV vaccine protects African green monkeys from RSV infection","volume":"30","author":"Jones","year":"2012","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.vaccine.2014.03.088","article-title":"Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model","volume":"32","author":"Jones","year":"2014","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CVI.00618-14","article-title":"Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children","volume":"22","author":"Adderson","year":"2015","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1084\/jem.115.5.903","article-title":"Growth characteristics of monkey kidney cell strains LLC-MK1, LLC-MK2, and LLC-MK2(NCTC-3196) and their utility in virus research","volume":"115","author":"Hull","year":"1962","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/intimm\/dxs107","article-title":"Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines","volume":"25","author":"Sealy","year":"2013","journal-title":"Int. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1073\/pnas.91.1.163","article-title":"Stimulation of transcytosis of the polymeric immunoglobulin receptor by dimeric IgA","volume":"91","author":"Song","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12514","article-title":"Complex immune correlates of protection in HIV-1 vaccine efficacy trials","volume":"275","author":"Tomaras","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Laszlofy, C., Fazekas, G., Barath, Z., and Vajo, Z. (2024). Evaluation of Vaccine Immunogenicity-Correlates to Real-World Protection: Influenza. Viruses, 16.","DOI":"10.3390\/v16030441"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2473795","DOI":"10.1080\/21645515.2025.2473795","article-title":"Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection","volume":"21","author":"Hwang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.coi.2022.102234","article-title":"The next frontier in vaccine design: Blending immune correlates of protection into rational vaccine design","volume":"78","author":"Britto","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/INF.0000000000000994","article-title":"Markers of Protection in Children and Adolescents Six to Fourteen Years After Primary Hepatitis B Vaccination in Real Life: A Pilot Study","volume":"35","author":"Huber","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00253-020-11050-8","article-title":"High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells","volume":"105","author":"Wu","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, Q., Luo, J., Li, B., Ye, Q., Xu, W., Gao, F., Zhou, L., Lu, W., Tan, W.S., and Li, X. (2024). Reduction in Interferon-Stimulated Genes Contributes to High-Yield Production of Influenza Virus in Suspension MDCK Cells. Vaccines, 12.","DOI":"10.3390\/vaccines12030287"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/4\/430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:56Z","timestamp":1760030276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/4\/430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["vaccines13040430"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13040430","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}